FDA Provides Suggestions for Point-of-Care 3D Printing of Devices 

Several 3D printed devices may be printed at the clinic rather than printed at a traditional manufacturing facility and shipped. But 3D printing operations still need to comply with FDA’s QSR and GMP requirements. FDA released a Discussion Paper listing three scenarios for 3D printed devices with examples and tips for complying with FDA’s requirements … Read more

FDA Releases Guidance for Wearables and Apps in Clinical Trials

FDA would like clinical trials using remote data collection devices such as wearable gadgets and phone apps to consider five factors that may influence the reliability and acceptability of the data generated. The devices or apps (software) must be diligently selected to assure it is suitable for the expected data, it should be verified and … Read more

Facebook Changes Ad Policies for Clinical Trials 

Facebook will stop offering a few popular tools for targeted advertising of clinical trials to potential participants soon. The tools together called “Detailed Targeting” allows presenting targeted advertisements to patients based on health conditions. These changes may affect trials that depend primarily on social media for finding patients such as cancer studies, neurological disorders and … Read more

Clinicaltrial.gov Website Gets a Facelift  

The clinicaltrials.gov website is undergoing modernization to be more user friendly and mobile optimized. The new website will evolve over the next year. It starts this week with a beta version which is an optional format for now as you can go back to the “classic” version. In a year’s time, the “classic” version will … Read more

FDA Updates the Clinical Outcome Assessment Compendium

Clinical Outcome Assessments (COAs) are the measures of the clinical response to a treatment as observed by a patient, their physician, an independent observer, or an objective measure of the patient’s performance following treatment with a drug or biologic. COAs are closely related to patient focused drug development where clinically relevant outcomes can and have … Read more

Did the EUA for Covid Tests, Kill the 510k for them?

Why is there only one diagnostic test for Covid cleared by FDA under the 510k pathway after almost 2 years of the pandemic? FDA has granted emergency use authorizations (EUA) to 423 Covid tests, but it has only given one device 510k clearance, that too in March of this year, 9 months ago. The 510k … Read more

FDA’s EUA for Covid LDTs Has Minimal Impact on Most LDTs 

This week FDA announced that it is going to require emergency use authorizations (EUA) for Lab Developed Tests (LDTs) intended for Covid diagnosis summarily reversing a decision last August that LDTs don’t need EUA. While this may seem like a major decision, it is not. The announcement is very specific to RT-PCR tests for Covid, … Read more

RWE Shows that Short-Course Antibiotic Treatment is Better and Safer

Real world data (RWD) and the resulting real world evidence (RWE) can provide unique and valuable information, otherwise hard to generate, on best practices for patient treatment in real-world health care settings. FDA supported two RWD studies, one in adults and the other in pediatric populations, to evaluate the duration of the antibiotic treatments for … Read more